A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer
Document Type
Article
Department
Haematology and Oncology, East Africa
Abstract
Purpose: To investigate the activity of carboplatin and cetuximab in NSCLC.
Patients and Methods: This was a single arm, multicenter phase II trial, and the primary objective was response rate.
Results: The overall response rate observed was 9% (95% confidence interval [CI], 3–19), the progression-free survival was 2.9 months (95% CI, 1.9–3.6), the median overall survival was 8.2 months (95% CI, 4.9–10.5), and 1-year survival rate was 33% (95% CI, 21–45).
Conclusion: The combination of carboplatin and cetuximab demonstrated lower activity than double agent platinum-based therapy and does not warrant further development
Publication (Name of Journal)
Cancer Investigation
DOI
https://doi.org/10.3109/07357900903286958
Recommended Citation
Stinchcombe, T.,
Bradford, D.,
Hensing, T.,
LaRocca, R.,
Saleh, M.,
Evans, T.,
Bakri, K.,
Socinski, M.
(2009). A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer. Cancer Investigation, 28(2).
Available at:
https://ecommons.aku.edu/eastafrica_fhs_mc_haematol_oncol/51
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Comments
This work was published before the author joined Aga Khan University.